Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer

Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer

Docetaxel (DTX) was the first chemotherapeutic agent to demonstrate significant efficacy in the treatment of men with metastatic castration-resistant prostate cancer. However, response to DTX is generally short-lived, and relapse eventually occurs due to emergence of drug-resistance. We previously e...

Full description

Bibliographic Details
Main Authors:	Thiago S. Lima, Luciano O. Souza, Diego Iglesias-Gato, Johanna Elversang, Flemming Steen Jørgensen, Tuula Kallunki, Martin A. Røder, Klaus Brasso, José M.A. Moreira
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Pharmacology
Subjects:	metastatic castration-resistant prostate cancer docetaxel resistance cellular models androgen independence drug repurposing
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.869461/full

Similar Items

Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance
by: Thiago S. Lima, et al.
Published: (2021-03-01)

Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer
by: Die Zhang, et al.
Published: (2023-03-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
by: María José Juan Fita, et al.
Published: (2023-10-01)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
by: Victor Omoboyede, et al.
Published: (2023-04-01)

Epithelial-Mesenchymal Transition in Docetaxel-Resistant Prostate Cancer
by: Camila Libardi do Amaral
Published: (2017-06-01)

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
by: A. V. Kondrashina, et al.
Published: (2018-05-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
by: Judith Passildas‐Jahanmohan, et al.
Published: (2021-04-01)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
by: Sang Eun Yoon, et al.
Published: (2019-05-01)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
by: Rebeca Lozano, et al.
Published: (2021-05-01)

Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study
by: Shuya Kandori, et al.
Published: (2016-12-01)

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
by: Stanislav Drápela, et al.
Published: (2020-10-01)

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
by: Li-Wen Chang, et al.
Published: (2021-01-01)

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2016-12-01)

Surface-enhanced Raman spectroscopy of serum predicts sensitivity to docetaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
by: Jianian Hu, et al.
Published: (2021-07-01)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
by: Kai-Jie Wu, et al.
Published: (2018-01-01)

A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer
by: Yuting Shan, et al.
Published: (2021-05-01)

Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
by: Darren M.C. Poon, et al.
Published: (2015-06-01)

Role of chemotherapy in prostate cancer
by: Rita Nader, et al.
Published: (2018-01-01)

Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01)

Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer
by: Hai-Hong Zhou, et al.
Published: (2019-12-01)

Docetaxel-induced radiation recall dermatitis
by: EG Kandemir, et al.
Published: (2005-01-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2018-04-01)

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2015-09-01)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01)

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
by: Xiang Cai, et al.
Published: (2023-05-01)

Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells
by: Fujun Li, et al.
Published: (2019-10-01)

Increased ABCC4 Expression Induced by ERRα Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
by: Houbao Huang, et al.
Published: (2020-08-01)

Seeking and Exploring Efficient Ways to Target Cancer
by: Tuula Kallunki
Published: (2020-09-01)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
by: Junru Chen, et al.
Published: (2022-01-01)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
by: Wei Ning, et al.
Published: (2023-09-01)

Docetaxel-Loaded Chitosan-Cholesterol Conjugate-Based Self-Assembled Nanoparticles for Overcoming Multidrug Resistance in Cancer Cells
by: Chao-Feng Mu, et al.
Published: (2020-08-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

New developments in the treatment of castration resistant prostate cancer
by: Roxanne Wadia, et al.
Published: (2014-08-01)

Granulocyte colony‐stimulating factor associated arteritis in a patient with castration‐resistant prostate cancer
by: Satoshi Nitta, et al.
Published: (2022-01-01)